tiprankstipranks
Trending News
More News >
SAGE Therapeutics (SAGE)
NASDAQ:SAGE
US Market

SAGE Therapeutics (SAGE) Earnings Dates, Call Summary & Reports

Compare
933 Followers

Earnings Data

Report Date
Aug 05, 2025
TBA Not Confirmed
Period Ending
2025 (Q2)
Consensus EPS Forecast
-0.95
Last Year’s EPS
-1.7
Same Quarter Last Year
Based on 14 Analysts Ratings

Earnings Call Summary

Earnings Call Date:Apr 29, 2025
|
% Change Since: -9.87%
|
Next Earnings Date:Aug 05, 2025
Earnings Call Sentiment|Positive
The earnings call presented a generally positive outlook with strong growth and milestones achieved for ZURZUVAE, a significant reduction in R&D expenses, and a clear focus on pipeline opportunities. However, there remains uncertainty with ongoing strategic alternatives and continued net losses, albeit reduced.
Company Guidance
During Sage Therapeutics' first quarter 2025 financial results conference call, several key metrics were highlighted. The company reported that ZURZUVAE, their oral treatment for postpartum depression (PPD), was shipped to over 3,000 women, marking a 22% increase from the fourth quarter of 2024. ZURZUVAE generated $13.8 million in collaboration revenue, a 21% rise compared to the previous quarter. The company noted that more than 70% of women prescribed ZURZUVAE received it as their first new treatment for PPD, and nearly 80% of prescriptions came from OB/GYNs. Additionally, Sage's R&D expenses decreased by 68% compared to the same period in 2024, reflecting a reorganization aimed at cost savings. The company has $424 million in cash, cash equivalents, and marketable securities as of March 31, 2025, expected to support operations through mid-2027.
Strong Start for ZURZUVAE in 2025
ZURZUVAE was shipped to over 3,000 women with PPD in Q1 2025, representing a 22% increase from Q4 2024. Collaboration revenue for ZURZUVAE was $13.8 million, a 21% increase from Q4 2024.
Significant Milestone for ZURZUVAE
Since its launch, ZURZUVAE has been shipped to over 10,000 women with PPD, marking a significant milestone in advancing patient care.
R&D Cost Reduction
R&D expenses were significantly reduced by 68% in Q1 2025 compared to the same period in 2024, and by nearly 40% compared to Q4 2024.
New Pipeline Opportunities
Prioritized clinical pipeline in neuropsychiatry and neurodevelopmental disorders, with potential opportunities for SAGE-319 and NMDA receptor NAM platform.
Financial Stability
Cash runway expected to support operations to mid-2027 with existing cash, equivalents, and marketable securities of $424 million as of March 31, 2025.

SAGE Therapeutics (SAGE) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

SAGE Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Aug 05, 2025
2025 (Q2)
-0.95 / -
-1.7
Apr 29, 2025
2025 (Q1)
-0.99 / -1.01
-1.843.89% (+0.79)
Feb 11, 2025
2024 (Q4)
-1.48 / -1.56
-0.55-183.64% (-1.01)
Oct 29, 2024
2024 (Q3)
-1.55 / -1.53
-3.3754.60% (+1.84)
Jul 31, 2024
2024 (Q2)
-1.65 / -1.70
-2.6836.57% (+0.98)
Apr 25, 2024
2024 (Q1)
-1.65 / -1.80
-2.4626.83% (+0.66)
Feb 14, 2024
2023 (Q4)
-1.28 / -0.55
-2.4777.73% (+1.92)
Nov 07, 2023
2023 (Q3)
-2.68 / -3.37
-2.31-45.89% (-1.06)
Aug 07, 2023
2023 (Q2)
-2.55 / -2.68
-2.13-25.82% (-0.55)
May 02, 2023
2023 (Q1)
-2.51 / -2.46
-2.07-18.84% (-0.39)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

SAGE Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Apr 29, 2025
$7.60$7.29-4.08%
Feb 11, 2025
$7.19$7.16-0.42%
Oct 29, 2024
$8.48$6.44-24.06%
Jul 31, 2024
$10.80$10.95+1.39%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does SAGE Therapeutics (SAGE) report earnings?
SAGE Therapeutics (SAGE) is schdueled to report earning on Aug 05, 2025, TBA Not Confirmed.
    What is SAGE Therapeutics (SAGE) earnings time?
    SAGE Therapeutics (SAGE) earnings time is at Aug 05, 2025, TBA Not Confirmed.
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is SAGE EPS forecast?
          SAGE EPS forecast for the fiscal quarter 2025 (Q2) is -0.95.

            SAGE Therapeutics (SAGE) Earnings News

            Sage (NASDAQ:SAGE) Plummets On FDA Snub for Zuranolone in Major Depression Disorder
            Premium
            Market News
            Sage (NASDAQ:SAGE) Plummets On FDA Snub for Zuranolone in Major Depression Disorder
            2y ago
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis